Suppr超能文献

[游离循环DNA血浆在甲状腺肿瘤术前诊断中的应用可能性]

[The possibility of using freely circulating DNA blood plasma in preoperative diagnosis of thyroid tumors].

作者信息

Kachko Vera A, Vanushko Vladimir E, Platonova Nadezhda M, Abrosimov Aleksandr Yu, Tely Sheva Ekaterina N, Snigireva Galina P

机构信息

I.M. Sechenov First Moscow State Medical University (Sechenov University).

Endocrinology Research Centre.

出版信息

Probl Endokrinol (Mosk). 2020 Jun 10;65(6):400-407. doi: 10.14341/probl11311.

Abstract

BACKGROUND

The feasibility of using molecular genetic markers for the diagnosis of thyroid tumors and the impact on the prognosis of thyroid cancer are being actively investigated. The most interesting are genes, the detection of which is associated not only with thyroid cancer, but also with a more aggressive course of the disease. The ability to diagnose the molecular profile of minimally invasive methods with the study of freely circulating DNA tumor tissue in blood plasma is a modern trend of medicine.

AIMS

to evaluate the frequency of somatic mutations in the «hot spots» of BRAF, KRAS, KRAS, EIF1AX and TERT genes in circulating DNA of blood plasma.

MATERIALS AND METHODS

Samples of DNA, extracted from the removed tumor and non-tumor thyroid tissue, were tested for the presence of somatic mutations in hot spots of the genes BRAF, KRAS, NRAS, TERT, and EIF1AX and then in identifying mutations and testing appropriate samples of free circulating DNA in blood plasma.

RESULTS

mutations in the» hot spots «of the BRAF gene (exon 15, codon area 600-601) were found in 54 patients, mutations in the» hot spots « of the NRAS gene (exon 3, codon 61) – in 12 patients; mutations in the hot spots of the KRAS, TERT and EIF1AX genes were not detected. In freely circulating blood plasma DNA, BRAF gene mutations were detected in 1 case, NRAS gene mutations were detected in 1 case.

CONCLUSIONS

the use of freely circulating DNA of blood plasma in the testing of the studied sample did not show the feasibility for the diagnosis of thyroid tumors.

摘要

背景

目前正在积极研究使用分子遗传标记诊断甲状腺肿瘤的可行性及其对甲状腺癌预后的影响。最受关注的是那些基因,其检测不仅与甲状腺癌相关,还与疾病更具侵袭性的病程有关。通过研究血浆中游离循环的肿瘤组织DNA来诊断微创方法的分子特征,是现代医学的一个趋势。

目的

评估血浆游离DNA中BRAF、KRAS、NRAS、EIF1AX和TERT基因“热点”区域的体细胞突变频率。

材料与方法

从切除的肿瘤和非肿瘤甲状腺组织中提取DNA样本,检测BRAF、KRAS、NRAS、TERT和EIF1AX基因热点区域的体细胞突变情况,然后鉴定突变并检测血浆中游离循环DNA的相应样本。

结果

54例患者的BRAF基因(第15外显子,密码子区域600 - 601)“热点”区域存在突变,12例患者的NRAS基因(第3外显子,密码子61)“热点”区域存在突变;未检测到KRAS、TERT和EIF1AX基因热点区域的突变。在血浆游离循环DNA中,检测到1例BRAF基因突变,1例NRAS基因突变。

结论

在所研究样本的检测中,使用血浆游离循环DNA未显示出诊断甲状腺肿瘤的可行性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验